Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75)

I M Stratton, C A Cull, A I Adler, D R Matthews, H A W Neil, R R Holman, I M Stratton, C A Cull, A I Adler, D R Matthews, H A W Neil, R R Holman

Abstract

Aims/hypothesis: The relative importance of glucose and blood pressure control in type 2 diabetes remains uncertain. We assessed interactive effects of glycaemia and systolic blood pressure (SBP) exposure on the risk of diabetic complications over time.

Subjects, materials and methods: HbA(1c) and SBP, measured annually for a median of 10.4 years in 4,320 newly diagnosed type 2 diabetic patients from the UK Prospective Diabetes Study (UKPDS), were categorised as updated mean values <6.0, 6.0-6.9, 7.0-7.9 or > or =8.0%, and <130, 130-139, 140-149 or > or =150 mmHg, respectively. Clinical outcomes were UKPDS predefined composite endpoints.

Results: The incidence of the "any diabetes-related endpoint" in the lowest (HbA(1c) <6.0%, SBP <130 mmHg) and highest (HbA(1c) > or =8%, SBP > or =150 mmHg) category combinations was 15 and 82 per 1,000 person-years, respectively, and 24 and 120 per 1,000 person-years in a Poisson model adjusted to white Caucasian male sex, age 50 to 54 years and diabetes duration of 7.5 to 12.5 years. Updated mean HbA(1c) and SBP effects were additive in an adjusted proportional hazards model with risk reductions of 21% per 1% HbA(1c) decrement and 11% per 10 mmHg SBP decrement. Endpoint rates obtained in the 887 patients randomised in both the glycaemia and hypertension intervention trial arms were consistent with the observational data. Those allocated to both intensive glucose and tight blood pressure control policies had fewer events than those allocated to either policy alone or to neither (p for trend 0.024).

Conclusions/interpretation: Risk of complications in type 2 diabetes is associated independently and additively with hyperglycaemia and hypertension. Intensive treatment of both these risk factors is required to minimise the incidence of complications.

References

    1. Lancet. 2000 Jan 22;355(9200):253-9
    1. Diabetes Res Clin Pract. 1995 May;28(2):103-17
    1. Diabetologia. 1996 Dec;39(12):1577-83
    1. Am J Epidemiol. 1986 Mar;123(3):504-16
    1. Arch Intern Med. 1991 Jun;151(6):1141-7
    1. J Am Geriatr Soc. 2000 Mar;48(3):264-7
    1. Diabetologia. 1991 Dec;34(12 ):877-90
    1. N Engl J Med. 2003 Jan 30;348(5):383-93
    1. Lancet. 1998 Sep 12;352(9131):837-53
    1. BMJ. 1999 Sep 4;319(7210):630-5
    1. Diabetes Care. 1991 Jul;14(7):665-71
    1. BMJ. 1998 Mar 14;316(7134):823-8
    1. Clin Chem. 1997 Oct;43(10):1913-8
    1. Clin Sci (Lond). 2001 Dec;101(6):671-9
    1. BMJ. 2000 Aug 12;321(7258):412-9
    1. Diabet Med. 1994 Jul;11(6):534-44
    1. JAMA. 1991 Feb 6;265(5):627-31
    1. Ann Intern Med. 1996 Jan 1;124(1 Pt 2):136-45
    1. BMJ. 2000 Aug 12;321(7258):405-12
    1. Arch Intern Med. 1994 Nov 14;154(21):2473-9
    1. BMJ. 1998 Sep 12;317(7160):713-20
    1. BMJ. 1998 Sep 12;317(7160):703-13
    1. BMJ. 1989 Nov 4;299(6708):1127-31
    1. Diabetes Res Clin Pract. 2000 Nov;50 Suppl 3:S5-13
    1. Diabet Med. 2005 Jul;22(7):882-8
    1. Diabetes Care. 1993 Feb;16(2):434-44
    1. Am Heart J. 1991 Feb;121(2 Pt 1):586-90

Source: PubMed

3
订阅